What This Bill Does · Plain English
Summary · Congress.gov
Ensuring Access to Essential Drugs Act This bill exempts certain brand-name drugs from the Medicare Part D Manufacturer Discount Program. Under the program, drug manufacturers provide discounts to beneficiaries who have incurred costs above the annual deductible under the Medicare prescription drug benefit. Specifically, the bill exempts from the program orally administered, brand-name drugs that are considered generics for purposes of the Medicaid Drug Rebate Program (per an exception granted by the Centers for Medicare & Medicaid Services).
Action Timeline
2025-03-06
Introduced in House
2025-03-06
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdicti
2025-03-06
Introduced in House
Frequently Asked Questions
Did HR.1922 pass?
HR.1922 is still alive. Current stage: COMMITTEE. Pass likelihood: 40%.
What does HR.1922 do?
Ensuring Access to Essential Drugs Act This bill exempts certain brand-name drugs from the Medicare Part D Manufacturer Discount Program. Under the program, drug manufacturers provide discounts to beneficiaries who have incurred costs above the annual deductible under the Medicare prescription drug benefit. Specifically, the bill exempts from the program orally administered, brand-name drugs that are considered generics for purposes of the Medicaid Drug Rebate Program (per an exception granted by the Centers for Medicare & Medicaid Services).
Who sponsored HR.1922?
HR.1922 was sponsored by Andrew R. Garbarino (R-New York).
Full Bill Text
119 HR 1922 IH: Ensuring Access to Essential Drugs Act U.S. House of Representatives 2025-03-06 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 119th CONGRESS 1st Session H. R. 1922 IN THE HOUSE OF REPRESENTATIVES March 6, 2025 Mr. Garbarino (for himself, Mrs. Harshbarger , and Mr. Suozzi ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to exempt certain drugs from the part D manufacturer discount program under the Medicare program. 1. Short title This Act may be cited as the Ensuring Access to Essential Drugs Act . 2. Exempting certain drugs from the part D manufacturer discount program under the Medicare program Section 1860D–14C(g)(2) of the Social Security Act (42 U.S.C. 1395w–114c(g)(2)) is amended— (1) in subparagraph (A), by striking and at the end; (2) in subparagraph (B), by striking the period and inserting ; and ; and (3) by adding at the end the following new subparagraph: (C) does not include an orally administered drug— (i) for which a new drug application was approved under section 505 of the Federal Food, Drug, and Cosmetic Act; and (ii) that has been granted a narrow exception permitting reclassification as a noninnovator multiple source drug under the Medicaid drug rebate program by the Centers for Medicare & Medicaid Services. .
Loading intelligence layer…